Retrospective analysis shows enfortumab vedotin does not impair renal function in patients with metastatic urothelial carcinoma, indicating its safety and efficacy.
EV did not significantly impair renal function in patients with mUC. Comparable efficacy and safety were observed regardless of baseline eGFR, supporting the feasibility of EV in patients with impaired renal function.
No takes yet. Share an insight, caveat, or question.
Kobari et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: